RxDoctor Payments Data

John Diaz, MD

Family Medicine · Naples, FLNPI 1588616072

Payments from drug & device makers

$169,435in general payments, 2019–2025

Across 640 payments — averaging $264.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$110K
  • Kaneka Medical America LLC$46K
  • Amgen$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • plus $8K from 48 others

What the payments were for

  • Consulting fees$20,55235%
  • Speaking & faculty fees$25,31043%
  • Food & beverage$12,75722%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$169,435 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$318,704
Medicare patients
250
Services billed
3,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab228$215,234
VascepaIcosapent Ethyl117$92,796
JardianceEmpagliflozin59$90,773
Praluent PenAlirocumab58$77,674
MounjaroTirzepatide60$74,721
NexletolBempedoic Acid77$59,372
NexlizetBempedoic Acid/Ezetimibe37$35,096
EliquisApixaban22$27,152
OzempicSemaglutide20$26,723
LivaloPitavastatin Calcium16$14,979
EntrestoSacubitril/Valsartan13$11,575
Ezetimibe326$7,531
Pitavastatin Calcium12$6,519
Icosapent Ethyl12$5,744
Rosuvastatin Calcium358$4,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Esperion Therapeutics, Inc.Nexletol, Nexlizet$395$94,468114 claims
Boehringer IngelheimJardiance$657$90,77359 claims
Lilly USA, LLCMounjaro$597$74,72160 claims
PfizerEliquis$1,006$27,15222 claims
Novo NordiskOzempic$1,320$26,72320 claims
Kowa Pharmaceuticals America, Inc.Livalo$392$14,97916 claims
NovartisEntresto$683$11,57513 claims
Almatica Pharma LLCSertraline Hcl$12$52378 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →